AdCLD-CoV19
Vaccine candidate against COVID-19
From Wikipedia, the free encyclopedia
AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,[2][3] a company from South Korea.[4]
TargetSARS-CoV-2
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.[5] In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.[6] Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.[7] In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.[8]
.svg){kind=small}
.png){kind=small}
